Affordable Access

deepdyve-link
Publisher Website

Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis

Authors
  • Turner, Hugo C1
  • 1 MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, UK , (United Kingdom)
Type
Published Article
Journal
International Health
Publisher
Oxford University Press
Publication Date
Dec 22, 2020
Volume
13
Issue
Suppl 1
Identifiers
DOI: 10.1093/inthealth/ihaa095
PMID: 33349885
PMCID: PMC7753169
Source
PubMed Central
Keywords
License
Unknown

Abstract

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the WHO in 2000. It aims to eliminate lymphatic filariasis as a public health problem. This paper summarises the key estimates of the cost-effectiveness and economic benefits related to the mass drug administration (MDA) provided by the GPELF. Several studies have investigated the cost-effectiveness of this MDA, estimating the cost per disability-adjusted life year (DALY) averted. These cost-effectiveness estimates have consistently classed the intervention as cost-effective and as favourable compared with other public health interventions conducted in low- and middle-income countries. Studies have also found that the MDA used for lymphatic filariasis control generates significant economic benefits. Although these studies are positive, there are still important gaps that warrant further health economic research (particularly, the evaluation of alternative interventions, further evaluation of morbidity management strategies and evaluation of interventions for settings coendemic with Loa loa ). To conclude, health economic studies for a programme as large as the GPELF are subject to uncertainty. That said, the GPELF has consistently been estimated to be cost-effective and to generate notable economic benefits by a number of independent studies.

Report this publication

Statistics

Seen <100 times